Fig. 4. B16vIII tumor growth was significantly inhibited in mice with vaccine-induced humoral and cellular antitumor immunity stimulated by multiepitope nanofibers.
(A) C57BL/6 mice received three subcutaneous immunizations (black arrows) and subsequently received 1 × 105 B16vIII tumor cells subcutaneously on the flank 14 days after final immunizations. PEPvIII-specific IgG titers in sera were monitored 1 week after each vaccination. (B) Both P/Tr/Td-fiber and P/Td-fibers stimulated strong PEPvIII-specific IgG responses after three immunizations (**P < 0.001 and ****P < 0.0001 by multiple comparison via two-way ANOVA with Tukey test, N = 10). (C) Both P/Tr/Td-fiber and Tr/Td-fiber and peptides/CFA emulsion group stimulated significant level of Trp2-specific CD8+ T cells on week 5 (*P < 0.05 and **P < 0.01 by multiple comparison using one-way ANOVA with Tukey test, N = 10). P/Tr/Td-fiber prophylactic immunization inhibited B16vIII tumor growth (D) and improved overall survival challenges (F). (D) Tumor growth measured over time (*P < 0.05, ***P < 0.001, and ****P < 0.0001, two-way ANOVA with Tukey test, N = 10). (E) Individual tumor growth curves. (F) Overall survival of tumor-bearing mice and median survival (*P < 0.05 and ****P < 0.0001 compared to P/Tr/Td-fiber group by log-rank test, N = 10).